Exelixis Inc. (EXEL) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Exelixis Inc. (EXEL:NASDAQ), powered by AI.
- Current Price
- $53.13
- P/E Ratio
- 18.4
- Market Cap
- 14.4B
- Sector
- Healthcare
What is the Exelixis Inc. stock price forecast?
Exelixis Inc. is currently trading at $53.13. View real-time AI analysis on Alpha Lenz.
What is Exelixis Inc. insider trading activity?
View the latest insider trading data for Exelixis Inc. on Alpha Lenz.
What is Exelixis Inc.'s P/E ratio?
Exelixis Inc.'s P/E ratio is 18.4.
Exelixis Inc.
NASDAQ · EXEL“Exelixis Inc. trades at a P/E of 18.4 (fair value) with strong ROE of 35.5%. 3Y revenue CAGR of 12.9% highlights clear growth momentum.”
Ask for details →Company Overview
Exelixis Inc. is a biopharmaceutical company focused on developing and commercializing small-molecule therapies for cancer treatment. Established in 1994, Exelixis has carved a niche in oncology by delivering highly targeted medicinal solutions. One of its cornerstone products, Cabometyx, is utilized in treating advanced renal cell carcinoma and hepatocellular carcinoma, significantly impacting the healthcare sector's approach to managing these cancers. Additionally, the company is engaged in a robust pipeline of projects aimed at diversifying its oncological therapeutic offerings. Exelixis' collaborations with other leading pharmaceutical entities enhance its research capabilities and extend its reach globally, reinforcing its role in the biopharmaceutical landscape. By focusing on unmet medical needs within the oncology sector, Exelixis plays a critical role in influencing both patient care and future therapeutic developments in cancer treatment.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Exelixis Inc. trades at a P/E of 18.4 (fair value) with strong ROE of 35.5%. 3Y revenue CAGR of 12.9% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Exelixis Inc. (ticker: EXEL) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 1,147 employees. Market cap is $14.4B.
The current price is $53.13 with a P/E ratio of 18.44x and P/B of 6.68x.
ROE is 35.53% and operating margin is 38.48%. Annual revenue is $2.3B.